HC Wainwright Cuts Bicara Therapeutics (NASDAQ:BCAX) Price Target to $44.00

Bicara Therapeutics (NASDAQ:BCAX) had its price target cut by research analysts at HC Wainwright from $45.00 to $44.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 316.27% from the stock’s current price.

BCAX has been the topic of a number of other reports. Cantor Fitzgerald reissued an “overweight” rating and set a $13.01 price target on shares of Bicara Therapeutics in a report on Thursday, March 13th. Wedbush reiterated an “outperform” rating and set a $31.00 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Finally, Stifel Nicolaus set a $48.00 target price on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $36.50.

Bicara Therapeutics Price Performance

Shares of Bicara Therapeutics stock opened at $10.57 on Monday. Bicara Therapeutics has a 12 month low of $10.52 and a 12 month high of $28.09. The business has a fifty day simple moving average of $13.07 and a two-hundred day simple moving average of $17.46.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.08). On average, sell-side analysts anticipate that Bicara Therapeutics will post -2.59 earnings per share for the current year.

Institutional Trading of Bicara Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System bought a new stake in shares of Bicara Therapeutics during the 4th quarter worth approximately $25,000. Spire Wealth Management bought a new position in Bicara Therapeutics in the 4th quarter worth about $31,000. BNP Paribas Financial Markets bought a new stake in shares of Bicara Therapeutics during the fourth quarter valued at approximately $32,000. Legal & General Group Plc bought a new position in Bicara Therapeutics in the fourth quarter worth approximately $33,000. Finally, Summit Investment Advisors Inc. bought a new stake in Bicara Therapeutics during the 4th quarter valued at $35,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.